Loading…
CEFADROXIL is a brand name for Cefadroxil. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: Cefadroxil is a cephalosporin antibiotic bactericidal in vitro against a wide range of Gram-positive and Gram-negative microorganisms. Cefadroxil is indicated in the treatment of the following infections when due to susceptible microorganisms. Respiratory tract infections: Tonsillitis, pharyngitis, lobar and…
Verbatim from this product's MHRA label. Tap a section to expand.
Adults and children weighing more than 40 kg (6 st. and 4 lbs): One to tow capsules (500 mg to 1 g) twice a day, depending upon the severity of infection. Alternatively, in skin and soft tissue and uncomplicated urinary tract infections, 1 g once a day.
In the treatment of beta-haemolytic streptococcal infections, Cefadroxil should be administered for at least 10 days. Adults and children (7years & above) weighing less than 40 kg (6 st. and 4lbs): One capsule (500 mg) twice a day.
Elderly:
No specific dosage recommendations or precautions for use in the elderly except to monitor those patients with impaired renal function. The bioavailability and consequent chemotherapeutic effects of cefadroxil are unaffected by food.
It may, therefore, be taken with meals or on an empty stomach.
Renal Impairment Dosage:
In patients with renal impairment, the dosage should be adjusted according to creatinine clearance rates to prevent drug accumulation and serum levels should be monitored. A modified dosage schedule is unnecessary in patients with creatinine clearance rates of greater than 50 ml/min.
73m2). Patients with renal insufficiency may be treated with an initial dose of 500 mg to 1000 mg of cefadroxil. 73m2 500-1000 mg 12 hrs Cefadroxil can be removed from the body by haemodialysis.
The most commonly reported side-effects are gastrointestinal disturbances and hypersensitivity phenomena. Undesirable effects reported are listed per System Organ Class and per frequency. Very common: (>1/10) Common: (>1/100, <1/10) Uncommon: (>1/1000, <1/100) Rare: (>1/10000, <1/1000) Very rare: (<1/10000), including isolated cases Infections and infestations Uncommon: Clinical pictures due to a growth of opportunistic organisms (fungi), such as vaginal mycoses (genital candidiasis), thrush Blood and the lymphatic system disorders Rare: Eosinophilia, thrombocytopenia, leucopenia, neutropenia, agranulocytosis: rare cases during prolonged use, which subside upon discontinuation of therapy.
Very rare:
Isolated cases of haemolytic anaemia of immunologic origin.
Immune system disorders Rare:
Serum sickness-like reactions Very rare: immediate allergic reaction (anaphylactic shock) Nervous and psychiatric system disorders Very rare: dizziness, headache, nervousness, sleeplessness Several cephalosporins have been implicated in triggering seizures, particularly in patients with renal impairment, when the dosage was not reduced.
If seizures associated with drug therapy occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated. Gastrointestinal disorders Common: nausea, vomiting, diarrhoea, dyspepsia, abdominal discomfort, abdominal pain, glossitis Very rare: Isolated cases of pseudo-membranous colitis Unknown frequency: Colitis has been reported.
Hepato-biliary disorders Rare: minor elevations of serum transaminases (ASAT, ALAT) and alkaline phosphatase Cases of cholestasis and idiosyncratic hepatic failure have been reported. 4)
Pseudomembranous colitis As with other broad spectrum antibiotics, pseudomembranous colitis has been reported. In case of severe and persistent diarrhoea, an antibiotic-associated pseudomembranous colitis should be considered. g. ). Antiperistaltics are contraindicated.
Clostridium difficile associated diarrhoea (CDAD) has been reported with use of nearly all antibacterial agents, including Cefadroxil, and may range in severity from mild diarrhoea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C.
difficile. C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy.
CDAD must be considered in all patients who present with diarrhoea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.
If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated History of gastro-intestinal disturbances Cefadroxil should be used with caution in patients with a history of gastro-intestinal disturbances particularly colitis.
2). Penicillin is the first drug of choice for the treatment of the Streptococcus pyogenes and for the prevention of rheumatic fever. Data for cefadroxil are not sufficiently substantial for prophylaxis therapy. As experience in premature infants and neonates is limited, the use of cefadroxil in these patients should only be undertaken with caution.
Cefadroxil is contraindicated in patients with: • History of hypersensitivity to cefadroxil, to any other cephalosporin or to any of the excipients of this product. • History of severe reactions to penicillins or to any other beta-lactam drugs
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Patients with history of allergies Special caution should be exercised in patients with history of severe allergies or asthma. In patients with a history of non severe hypersensitivity to penicillins, or other non- cephalosporin beta–lactam drugs, cefadroxil should be used with special caution as cross allergies occur (incidence 5-10%).
There is evidence of partial cross- allergenicity between the penicillins and the cephalosporins. Should an allergic reaction to cefadroxil occur, the drug should be discontinued and the patient treated with the usual agents (pressor amines, corticosteroids and/or antihistamines), depending on the severity of the reaction.
Patients who are allergic to aspirin have greater chances of developing an allergic reaction to one of the ingredients (colouring agent) in this medicine, namely Carmoisine (E122). ) and suitable countermeasures should be taken (sympathomimetics, corticosteroids and/or antihistaminics).
2 Posology). Prolonged use Particularly on prolonged use frequent checks on the blood count and regular hepatic and renal function tests are advisable. g. candida) can occur on prolonged treatment with cefadroxil. Severe life-threatening infections or those which require higher posology or repetitive administrations per day may benefit of parenteral cephalosporins.
The result of the Coombs' test can be transiently positive during or after treatment with cefadroxil. In haematologic studies or in transfusion cross-matching procedures when antiglobulin tests are performed on the minor side or in Coombs’ testing of newborns whose mothers have received cephalosporin antibiotics before parturition, it should be recognized that a positive Coombs’ test may be due to the drug